← Russell 3000 cross-section

AVTR Avantor, Inc.

Trailing twelve months to 2026-03-31 · as filed 2026-04-29, not restated
Healthcare

Scale

Market cap
$9.9bn
Revenue TTM
$6.6bn
Net income TTM
$-551m
Free cash flow
$439m
Composite score
44.6
Sector rank
#721

Valuation

P / E
EV / EBITDA
EV / sales
2.0
FCF yield
4.44%
Earnings yield vs 10-yr
-10.31pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-8.4%
EBITDA margin
ROE
-9.9%
ROIC
-3.2%
Revenue growth
-2.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net sales for the three months ended June 30, 2026 increased by 0.5%, which included a 0.4% organic net sales decrease compared to the same period in 2025. See “Results of operations” for a reconciliation and explanation of changes of net sales growth (decline) to organic net sales growth (decline). These measures are discussed in the section entitled “Results of operations”; • Organic net sales growth (decline) , which is a non-GAAP measure discussed in the section entitled “Results of operations.” Organic net sales growth (decline) eliminates from our reported net sales change the impacts of revenues from acquisitions and divestitures that occurred in the last year (as applicable) and chan …Avantor, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →